Skip to main content

Table 2 Association of NPAS2 rs6542993 with BCR in localized prostate cancer patients treated with RP

From: Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression

Gene

SNP

Genotype

No. of patients

No. of events

5-year survival rate (%)

P a

P b

HR (95% CI)

P c

NPAS2

rs6542993

AA

169

63

59.0

  

1.00

 
  

AT

229

90

58.8

  

1.40 (0.99–1.98)

0.059

  

TT

57

29

41.6

  

2.34 (1.45–3.79)

0.001

  

AT/TT vs AA

   

0.164

0.153

1.53 (1.10–2.14)

0.012

  

TT vs AA/AT

   

0.034

0.028

1.92 (1.25–2.94)

0.003

  

Trend

   

0.039

0.042

1.50 (1.18–1.91)

0.001

  1. PSA, prostate-specific antigen; RP, radical prostatectomy; SNP, single nucleotide polymorphism; HR, hazard ratio; 95% CI, 95% confidence interval
  2. P < 0.05 are in italicsface
  3. aP values were calculated using the log-rank test
  4. bP values were calculated after correcting for multiple tests by 1000 bootstrap resampling
  5. cHRs were adjusted for age, PSA at diagnosis, pathologic Gleason score, and pathologic stage